Aerovate Therapeutics downgraded by TD Cowen
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen downgraded Aerovate Therapeutics from Buy to Hold
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/18/2024 | $27.00 → $2.00 | Outperform → In-line | Evercore ISI |
6/18/2024 | Buy → Hold | TD Cowen | |
6/18/2024 | $35.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
6/17/2024 | Buy → Neutral | Guggenheim | |
6/17/2024 | Buy → Neutral | BTIG Research | |
6/17/2024 | $41.00 → $3.00 | Outperform → Neutral | Wedbush |
3/25/2024 | $21.00 → $65.00 | Buy | Jefferies |
12/8/2023 | $35.00 | Equal Weight | Wells Fargo |